Janssen is ranked in the top ten companies worldwide across all industry sectors in relation to research and development, investing a significant portion of its total pharmaceutical sales income.
In Ireland, we recognise the benefit of bringing clinical trials here in building Ireland’s reputation for research excellence and in providing patients with access to some of our most cutting-edge investigational medicines.
We work closely with the Irish scientific community, including Cancer Trials Ireland and Blood Cancer Network Ireland, to bring as many clinical trials here as possible, thereby extending Ireland’s R&D footprint.
For example, in haematology, we have supported numerous studies, led by Irish physicians, with the purpose of advancing scientific knowledge and investigating treatment options.
Janssen is also supporting the first clinical trial in CAR-T treatment of the blood cancer, multiple myeloma, in Ireland.
As a member of the Irish Pharmaceutical Healthcare Association (IPHA), Janssen is working to reform how clinical trials are conducted in Ireland with the ultimate goal of increasing the number of clinical trials taking place here.
Janssen Data Transparency Policy
We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our medicines and providers who prescribe them.
We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries, publication of results in peer reviewed journals, and sharing of Clinical Study Reports (CSRs).
For more information about our clinical trials please visit:
CP-372419 l February 2023